- Home
- VTYX vs BARK Comparison
VTYX vs BARK Comparison
Compare VTYX & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- BARK
- Stock Information
- Founded
- VTYX 2018
- BARK 2011
- Country
- VTYX United States
- BARK United States
- Employees
- VTYX N/A
- BARK N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- BARK Department/Specialty Retail Stores
- Sector
- VTYX Health Care
- BARK Consumer Discretionary
- Exchange
- VTYX Nasdaq
- BARK Nasdaq
- Market Cap
- VTYX 154.9M
- BARK 146.0M
- IPO Year
- VTYX 2021
- BARK N/A
- Fundamental
- Price
- VTYX $3.65
- BARK $0.75
- Analyst Decision
- VTYX Buy
- BARK Strong Buy
- Analyst Count
- VTYX 3
- BARK 3
- Target Price
- VTYX $10.00
- BARK $2.50
- AVG Volume (30 Days)
- VTYX 1.5M
- BARK 896.5K
- Earning Date
- VTYX 11-06-2025
- BARK 11-06-2025
- Dividend Yield
- VTYX N/A
- BARK N/A
- EPS Growth
- VTYX N/A
- BARK N/A
- EPS
- VTYX N/A
- BARK N/A
- Revenue
- VTYX N/A
- BARK $470,831,000.00
- Revenue This Year
- VTYX N/A
- BARK N/A
- Revenue Next Year
- VTYX N/A
- BARK $6.25
- P/E Ratio
- VTYX N/A
- BARK N/A
- Revenue Growth
- VTYX N/A
- BARK N/A
- 52 Week Low
- VTYX $0.78
- BARK $0.73
- 52 Week High
- VTYX $4.05
- BARK $2.56
- Technical
- Relative Strength Index (RSI)
- VTYX 62.22
- BARK 37.69
- Support Level
- VTYX $3.48
- BARK $0.80
- Resistance Level
- VTYX $4.04
- BARK $0.88
- Average True Range (ATR)
- VTYX 0.30
- BARK 0.04
- MACD
- VTYX 0.04
- BARK -0.00
- Stochastic Oscillator
- VTYX 72.93
- BARK 9.02
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.